Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Hassler, M; Micksche, M; Stockhammer, G; Pichler, J; Payer, F; Abuja, B; Deinsberger, R; Marosi, C.
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Wien Klin Wochenschr. 2006; 118(7-8):230-238 Doi: 10.1007/s00508-006-0576-3
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Payer Franz

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Background: The use of chemotherapy in patients with malignant gliomas has remained a controversial issue even after the publication of favorable study data and a meta-analysis. The present study was initiated to support the use of chemotherapy in patients with relapsed high-grade gliomas (HGG). Patients and methods: Six Austrian centers recruited 43 patients with histologically confirmed HGG at first recurrence. Twelve chemotherapy-naive patients received oral temozolomide at a dose of 200 mg/m(2) once a day for five consecutive days and 26 patients a dose of 150 mg/m2 also for five days after various first-line chemotherapies. TMZ treatment was repeated every four weeks for a total of six cycles. Results: Twenty-one patients (52.5%) received at least six cycles of therapy. Two patients experienced complete remission and eight patients a partial response. Twenty patients survived at one year after enrolment in the study; eight patients survived beyond three years of follow-up. Hematological toxicities consisted of three thrombocytopenias G4 and 35 lymphocytopenias G3 and G4; these did not cause interstitial pneumonia or require inpatient treatment. Non-hematological toxicities were rare and without clinical relevance. Patients' quality of life was maintained during treatment. Conclusion: The study data confirm the feasibility and efficacy of chemotherapy with temozolomide in patients with relapsed/progressive HGG.

Find related publications in this database (using NLM MeSH Indexing)

Adolescent -

Adult -

Aged -

Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - adverse effects

Antineoplastic Agents, Alkylating - epidemiology

Brain Neoplasms - drug therapy Brain Neoplasms - mortality

Dacarbazine - administration & dosage Dacarbazine - adverse effects Dacarbazine - analogs & derivatives

Female -

Glioma - drug therapy

Humans -

Male -

Middle Aged -

Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - prevention & control

Prognosis -

Risk Assessment - methods

Risk Factors -

Survival Rate -

Treatment Outcome -

Find related publications in this database (Keywords)

glioblastoma multiforme

recurrent high-grade glioma

temozolomide

© Med Uni Graz • Imprint